Arrowhead Research | ARWR - Equity Capital And Reserves


Arrowhead Research reported $568.42M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Ligand Pharmaceuticals USD 950.17M 121.64M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 9.33B 69M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
TG Therapeutics USD 607.22M 330.79M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025
Xencor USD 625.32M 4.96M Sep/2025